BAKERSFIELD, Calif. (KERO) — Medicare is currently looking at whether is should cover the new Alzheimer's drug, aduhelm.
The drug comes with a $56,000 yearly price tag. It's also been criticized for not having enough evidence showing that it is beneficial to Alzheimer's patients.
A final decision on coverage isn't expected until spring of next year, but an initial ruling could happen before then.
